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Abstract
Despite the importance of placenta in mediating rapid physiological changes in pregnancy, data on temporal dynamics of
placental gene expression are limited. We completed the first transcriptome profiling of human placental gene expression
dynamics (GeneChips, AffymetrixH; ,47,000 transcripts) from early to mid-gestation (n = 10; gestational weeks 5–18) and
report 154 genes with significant transcriptional changes (ANOVA, FDR P,0.1). TaqMan RT-qPCR analysis (n = 43; gestational
weeks 5–41) confirmed a significant (ANOVA and t-test, FDR P,0.05) mid-gestational peak of placental gene expression for
BMP5, CCNG2, CDH11, FST, GATM, GPR183, ITGBL1, PLAGL1, SLC16A10 and STC1, followed by sharp decrease in mRNA levels at
term (t-test, FDR P,0.05). We hypothesized that normal course of late pregnancy may be affected when genes characteristic
to mid-gestation placenta remain highly expressed until term, and analyzed their expression in term placentas from normal
and complicated pregnancies [preeclampsia (PE), n = 12; gestational diabetes mellitus (GDM), n = 12; small- and large-for-
gestational-age newborns (SGA, LGA), n = 12+12]. STC1 (stanniocalcin 1) exhibited increased mRNA levels in all studied
complications, with the most significant effect in PE- and SGA-groups (t-test, FDR P,0.05). In post-partum maternal plasma,
the highest STC1 hormone levels (ELISA, n = 129) were found in women who had developed PE and delivered a SGA
newborn (median 731 vs 418 pg/ml in controls; ANCOVA, P = 0.00048). Significantly higher expression (t-test, FDR P,0.05)
of CCNG2 and LYPD6 accompanied with enhanced immunostaining of the protein was detected in placental sections of PE
and GDM cases (n = 15). Our study demonstrates the importance of temporal dynamics of placental transcriptional
regulation across three trimesters of gestation. Interestingly, many genes with high expression in mid-gestation placenta
have also been implicated in adult complex disease, promoting the discussion on the role of placenta in developmental
programming. The discovery of elevated maternal plasma STC1 in pregnancy complications warrants further investigations
of its potential as a biomarker.
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Copyright:  2012 Uusküla et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants to M.L.: Wellcome Trust International Senior Research Fellowship in Biomedical Science in Central Europe [070191/
Z/03/A], Estonian Science Foundation grants [ETF7471, ETF9030], Estonian Ministry of Education and Science core grant [SF0180022s12], Howard Hughes Medical
Institute International Scholarship Grant [#55005617]. L.U. was the recipient of the Seitsmes Sammas Stipend provided by Tartu University Foundation. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: maris.laan@ut.ee (ML); Juri.Reimand@utoronto.ca (JR)
Introduction
Placenta is a highly specialized temporary organ responsible for
the normal progression of pregnancy in mammals. Defects in
implantation, placental development and maturation lead to
complications in pregnancy and newborns [1]. Aberrant placental
expression of apoptosis and inflammation-related genes in early
pregnancy was found in recurrent miscarriage [Kristiina Rull,
unpublished data] and hydatidiform mole samples [2]. Altered
placental transcription of metabolic regulatory genes has been
associated to affected fetal growth and maternal pregnancy
complications such as preeclampsia (PE) and gestational diabetes
mellitus (GDM). Differential expression of some genes is common
to several pregnancy complications, serving as biomarkers for
malfunctioning placenta (e.g. FLT1, Fms-related tyrosine kinase 1;
LEP, Leptin; PIGF, Placental-derived growth factor; CRH,
Corticotropin-releasing hormone; ENG, Endoglin) [3–8].
Despite the great importance of placenta in mediating the rapid
physiological changes in pregnancy, data on the temporal
dynamics of human placental gene expression are limited.
Large-scale differences in DNA methylation levels between first,
second and third trimesters support the gestational-age dependent
function of placental genes [9]. So far, only three published studies
focus on gene expression in term placenta compared to either early
[10] or mid-gestation pregnancy [11], or both [12]. All studies
agree that global gene expression undergoes a profound transfor-
mation at the end of pregnancy, affecting up to 25% of placental
transcriptome [10] and involving coordinated up- or down-
regulation of functionally linked loci to achieve rapid changes in
placental function [11]. This appears to support the preparation of
the maternal organism for parturition and the fetal organism for
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postnatal life. Genes regulating cell cycle, differentiation and
motility, macromolecule biosynthetic and metabolic process, and
angiogenesis are up-regulated in early pregnancy, whereas genes
involved in lipid and chemosensory metabolism, stress response,
signal transduction and ion transport are highly expressed in term
placenta [11].
Another critical time-point in human pregnancy and placental
function is the switch from early to mid-gestation. In early
pregnancy, normal trophoblast development is the key for
successful implantation and formation of maternal-fetal interface
that facilitates the dialogue between the two organisms. Mid-
gestation placenta supports proportional fetal growth, organ
development and fine-scale differentiation, as well as continuing
maternal adaptation to pregnancy. Only one published study has
compared gene expression differences between first (45–59 days)
and second (109–115 days) trimester placentae and reported 61
differentially expressed loci that have been implicated in
pregnancy, reproductive physiolology and interaction between
organisms [12]. However, the authors were focused on microarray
data analysis, which was not followed by any experimental
confirmation or biomedical implication.
The present study had three main aims: (i) transcriptome
profiling of genes with significant expressional changes in placenta
in progression from early to mid-pregnancy, and experimental
confirmation of mid-gestation specific gene expression using
Taqman qPCR in an extended sample; (ii) investigation of the
novel hypothesis that the normal course of late pregnancy may be
affected when the genes characteristic to mid-gestation placental
transcriptome remain highly expressed until term; (iii) exploring
the protein expression of the most prominent identified genes in
pregnancy complications, and pilot evaluation of their applicabil-
ity as biomarkers.
The study reports 154 placental transcripts with significant
change in expression levels from gestational weeks 5 to 18. The
major advancement in the present study in contrast to earlier
publications is the experimental validation of 24 loci from
microarray analysis. Furthermore, we confirmed highly significant
distinct mid-gestational peaks of gene expression for 10 genes in an
extended sample-set of first, second and term placentae (n = 43). In
support of our study hypothesis, several mid-gestation genes
exhibited aberrant placental expression in complicated pregnan-
cies at term, and alterations at the protein level were confirmed for
CCNG2 (cyclin-G2), LYPD6 (LY6/PLAUR domain containing
protein 6) and STC1 (stanniocalcin-1). Our findings have direct
potential for biomedical implications as we demonstrate highly
significant elevated concentration of circulating hormone STC1 in
the maternal serum in PE patients and especially in the PE
subgroup accompanied by affected fetal growth. This warrants
further investigations of STC1 as a prognostic biomarker of
pregnancy outcome. As an additional novel finding, most of the
identified genes specifically up-regulated in mid-gestation placenta
have also been implicated in adult complex diseases.
Materials and Methods
Ethics Statements
The study was approved by the Ethics Review Committee of
Human Research of the University of Tartu, Estonia (permissions
no 117/9, 16.06.2003; 146/18, 27.02.2006; 150/33, 18.06.2006;
158/80, 26.03.2007; 180/M-15, 23.03.2009). A written informed
consent to participate in the study was obtained from each
individual prior to recruitment. All study participants were
recruited at the Women’s Clinic of Tartu University Hospital,
Estonia in 2003–2011, and were of white European ancestry and
living in Estonia.
Early and Mid-pregnancy Study Group
Placental samples were obtained from females who underwent
(a) elective (surgical) termination of pregnancy during first
trimester (n = 23; gestational age 5–13 weeks, median 8 weeks, 6
days [38–91 days, median 60 days]; median maternal age 27
years, range 18–38 years) or (b) therapeutic medically induced
abortion during second trimester due to maternal medical risks of
pregnancy, where no fetal anomalies were detected (n = 8;
gestational age 17–21 weeks, median 18 weeks, 5 days [120–147
days, median 131 days]; median maternal age 23 years, range 18–
39 years).
REPROMETA Sample Collection
REPROgrammed fetal and/or maternal METAbolism (RE-
PROMETA) sample collection harbors clinical data and biological
material from singleton pregnancies at term representing gesta-
tional weeks 36–42. Information about mother’s diseases, smoking,
somatometric data, and childbirth history was obtained from
medical records during the course of pregnancy and after birth.
Fetal outcome data from delivery included weeks of gestation,
birth weight, birth length, head and abdominal circumferences,
and placental weight. Cases with documented fetal anomalies,
chromosomal abnormalities, families with history of inherited
diseases and patients with known pre-existing diabetes mellitus,
chronic hypertension and chronic renal disease were excluded.
Detailed characteristics of REPROMETA samples for RT-qPCR
(n = 60) and ELISA (n = 129) experiments are given in Table 1.
The description of the sub-sample used for immunohistochemistry
experiments (n = 15) is provided in Table S1.
The REPROMETA participants were stratified in clinical
subgroups based on the birth weight of a newborn and the
absence/presence of maternal pregnancy-specific complications.
The control group comprised of uncomplicated pregnancies
resulting in the birth of newborn with the weight appropriate-
for-gestational age (AGA, birth-weight between 10–90 percentile;
n = 40; median gestational age 281 days, range 259–291 days;
median maternal age 27 years, range 18–40 years). Study groups
of disturbed fetal growth comprised of newborns born as (i) small-
for-gestational age (SGA, ,10th percentile; n = 27; median
gestational age 271, range 253–289 days; median maternal age
25 years, range 18–40 years) and (ii) large-for-gestational age
(LGA, .90th percentile; n = 16; median gestational age 285.5,
range 267–292 days; median maternal age 28 years, range 20–40
years). The weight percentiles for defining SGA and LGA were
calculated on the basis of data from Estonian Medical Birth
Registry [13].
Study groups of maternal pregnancy complications included
maternal (i) preeclampsia (PE; n = 16; median gestational age 265,
range 253–287 days; median maternal age 26 years, range 19–39
years) and (ii) gestational diabetes mellitus (GDM; n = 30;
gestational age of median 276, range 253–293 days; median
maternal age 31 years, range 21–42 years). Seven newborns in PE
group were additionally classified as SGA and twelve newborns in
GDM group as LGA. All PE cases represented the severe form of
late-onset preeclamptic pregnancies and were defined as hyper-
tensive (systolic blood pressure $160 mmHg and/or diastolic
blood pressure $110 mmHg) and/or had proteinuria of $5 g in
24 hours. GDM was diagnosed when 75 g oral glucose tolerance
test (OGTT) performed at 24–28 weeks of gestation revealed
either a fasting venous plasma glucose level of .4.8 mmol/l, and/
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or at 1 h and 2 h plasma glucose level of .10 mmol/l and
.8.7 mmol/l glucose, respectively.
RNA Extraction
Full-thickness blocks of 1–3 cm were taken from a middle
region of mid-gestation and term placenta within 2 h after
medically induced abortion, caesarean section or vaginal delivery.
The sampled full-thickness blocks involved all placental layers.
First trimester samples were obtained after elective (surgical)
termination of pregnancy. Collected tissue samples were snap-
frozen in liquid nitrogen and stored at 280uC or placed
immediately into RNAlater solution (Ambion Inc, Austin TX)
and kept at 220uC until RNA isolation.
Total RNA was extracted from 200–300 mg of homogenized
placental tissue containing various placental cell types using
TRIzol reagent (Invitrogen, Carlsbad, CA) and purified with
NucleoSpinH II Isolation Kit (Macherey-Nagel GmbH & Co. KG,
Düren, Germany) according to the manufacturers’ protocols.
Purity level and concentration of isolated total RNA was measured
using NanoDropH ND-1000 UV-Vis spectrophotometer (Nano-
Drop Technologies, Inc., Wilmington, DE, USA).
Microarray Hybridization
One microgram of total RNA was reverse transcribed to cDNA
(SuperScriptTM III First Strand Synthesis SuperMix kit, Invitro-
gen, Carlsbad, CA) and subjected to microarray analysis.
Expression of ,47,000 transcripts in second (4 samples) and first
trimester (6 samples) placentae was addressed using Affymetrix
Human Genome U133 plus 2.0 GeneChip microarrays following
manufacturer’s instructions. Briefly, complementary RNA (cRNA)
was synthesized using cDNA templates by in vitro transcription
reaction and labeled with biotin in the presence of T7 RNA
Polymerase and biotinylated nucleotide/ribonucleotide mix. Bio-
tin-labeled cRNA probes were purified, fragmented and hybrid-
ized to GeneChip expression arrays.
Table 1. Maternal and offspring characteristics of REPROMETA samples used in the study for RT-qPCR and ELISA experiments.
Mother and offspring characteristics Control SGA LGA PE GDM
A. Placental mRNA expression by RT-qPCR (n = 60 samples)
No of women [nulliparity] 12 [9] 12 [7] 12 [5] 12 [8] 12 [4]
Maternal age (yr) 26.5 (21; 38) 26.5 (18; 34) 26.5 (20; 40) 27.5 (19; 39) 33 (22; 39)*
Maternal height (cm) 166 (152; 175) 167 (163; 171) 168 (156; 180) 170 (156; 178) 161 (150; 173)
Maternal pre-pregnancy weight (kg) 58 (48; 74) 56 (47; 72) 66.5 (55; 85)* 67 (57; 89)* 66.5 (49; 107)
Gestational weight gain (kg) 13 (9; 24) 13 (10; 22) 17 (9; 33) 13 (6; 21.5) 15 (3; 26)
Delivery mode (vaginal/c-section) 10/2 10/2 4/8* 3/9* 4/8*
Smokers during pregnancy (n) 0 1 0 1 0
Gestational age at birth (d) 277 (259; 291) 270.5 (253; 289) 290.5 (284; 292)* 264.5 (253; 287)* 274.5 (253; 293)
Baby’s birth-weight (g) 3574 (2890; 4220) 2580 (2177; 2870)* 4727 (4588; 5010)* 2853 (2178; 4250)* 4054 (3154; 5420)*
Baby’s birth length (cm) 51 (49; 55) 46.5 (42; 49)* 54 (51; 57)* 48 (45; 51)* 52 (48; 55)
Baby’s head circumference (cm) 35 (33; 36.5) 32 (29; 35)* 37 (35.5; 39)* 34 (31.5; 37) 36.5 (34; 38)*
Baby’s abdominal circumference (cm) 34 (33; 36) 30 (28.5; 34)* 37 (36; 40)* 32 (28.5; 37.5)* 36 (32; 40.5)*
Placental weight (g) 520 (390; 750) 452.5 (381; 600) 790 (640; 1050)* 450 (340; 770) 645 (525; 860)*
No of newborns born SGA/LGA 0/0 12/0 0/12 4/0 0/6
No of boys/girls 6/6 5/7 6/6 9/3 5/7
B. Maternal blood serum analysis of STC1 by ELISA (n = 129 samples)
No of women [nulliparity] 40 [20] 27 [18] 16 [8] 16 [11] 30 [13]
Maternal age (yr) 27 (18; 40) 25 (18; 40) 28 (20; 40) 26 (19; 39) 31 (21; 42)*
Maternal height (cm) 165.5 (152; 175) 166 (153; 173) 167.5 (156; 180) 170 (156; 178)* 165.5 (150; 178)
Maternal pre-pregnancy weight (kg) 58.5 (48; 78) 56 (47; 72) 68 (57; 94)* 68.75 (53; 98)* 69 (46; 122)*
Gestational weight gain (kg) 15 (5; 25) 12.5 (8.5; 22) 17 (9; 33) 14 (6; 26) 14.3 (3; 26)
Delivery mode (vaginal/c-section) 35/5 19/8* 6/10* 5/11* 16/14*
Smokers during pregnancy (n) 1 4 0 1 0
Gestational age at birth (d) 281 (259; 291) 271 (253; 289)* 285.5 (267; 292)* 265 (253; 287)* 276 (253; 293)
Baby’s birth-weight (g) 3626 (2722; 4270) 2580 (2004; 2992)* 4717 (4364; 5050)* 2888 (2170; 4250)* 4065 (2934; 4964)*
Baby’s birth length (cm) 51 (48; 55) 47 (42; 49)* 53.5 (51; 57)* 48 (45; 51)* 51 (48; 54)
Placental weight (g) 550 (370; 800) 440 (200; 650)* 780 (640; 970)* 450 (340; 770) 635 (410; 1060)
No of newborns born SGA/LGA 0/0 27/0 0/16 7/0 0/12
No of boys/girls 19/21 7/20 9/7 9/7 13/17
Data are given as medians with ranges, except where indicated differently.
Nulliparity = no previous childbirth.
*P,0.05 vs. control group, Mann-Whitney U or Fisher’s exact test.
SGA, small-for-gestational age; LGA, large-for-gestational age; PE, preeclampsia; GDM, gestational diabetes mellitus; yr, years; d, days.
doi:10.1371/journal.pone.0049248.t001
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Statistical Analysis of Microarray Data
Microarray data of analyzed placental samples is MIAME
compliant and the raw datasets have been deposited to a MIAME
compliant database, the Gene Expression Omnibus (GEO) data
repository (early pregnancy, n = 6, accession no GSE22490; mid-
pregnancy, n = 4, accession no GSE37901). Quality control (QC),
pre-processing and linear modeling were performed using R-based
Bioconductor packages affy and limma [14] (Figure S1). GeneChip
CEL-files were imported to dChip [15] and analyzed using perfect
match-mismatch (PM/MM) modeling and invariant set normal-
ization. The genes with high signal intensity were filtered (dChip
signal threshold = 100).
The expression value of each gene was modeled as the linear
function of gestational age (duration of gestation) of associated
samples (n = 10; gestational days 38, 55, 2656, 81, 91, 120, 121,
126, 132). Statistical significance of the time-dependent gene
expression model was evaluated with an ANOVA (analysis of
variance) test that comparatively evaluated the variance in a null,
time-independent model of gene expression. To lower the
probability of apparently significant results arising from repeated
statistical tests for thousands of genes, Benjamini-Hochberg False
Discovery Rate (FDR) multiple testing corrections were used [16].
Additionally, empirical Bayes moderated t-test with FDR correc-
tion was used for group comparison between first (n = 6;
gestational days 38, 55, 2656, 81, 91) and second (n = 4;
gestational days 120, 121, 126, 132) trimester samples (details
are provided in Text S1).
Functional enrichment analysis of significantly differentially
expressed genes was carried out with g:Profiler software [17],
using default settings except for those described below (g:Profiler
with data from Ensembl 65). Analysis was carried out separately
for up-regulated genes and down-regulated genes. The back-
ground gene set for statistical testing included all genes on the
Affymetrix Human Genome U133 plus 2.0 GeneChip platform.
Benjamini-Hochberg (FDR) method was used for correcting
enrichment P-values for multiple testing [16]. Computationally
predicted functional evidence from Transfac, BioGrid and
MirBase datasets was filtered from final results.
Reverse Transcription Quantitative PCR (RT-qPCR)
Taqman RT-qPCR assays were performed for 14 genes with
significant P-values (ANOVA, FDR-corrected P,0.05) from
dynamic gestation-age dependent microarray analysis; for two
genes (GMPPB, GDP-mannose pyrophosphorylase B; LOC131185,
RAD23 homolog B (S. cerevisiae) pseudogene) TaqMan assays were
not available (Table S2). Taqman RT-qPCR experiments were
performed for additional ten genes with suggestive P-values in
microarray dataset (ANOVA, FDR-corrected 0.05#P,0.1): (i)
previously described placental transcriptional dynamics (CDH11,
cadherin 11; STC1; CCNG2; NEDD9, neural precursor cell
expressed developmentally down-regulated 9; ZFP36L1, zinc
finger protein 36, C3H type-like 1) [11,12]; (ii) mammalian
imprinted genes (PLAGL1, pleiomorphic adenoma gene-like 1;
MEG3, maternally expressed 3; GATM, glycine amidinotransfer-
ase) [18–20]; (iii) lowest borderline P-value (SNX18, sorting nexin
18; P = 0.0502) or gene-probe representing highest expressional
change (BMP5, bone morphogenetic protein 5; fold change 58.89)
(Table S2). In total, mRNA level of 24 genes (Table S3) was
assessed by Taqman RT-qPCR in samples from uncomplicated
early (n = 23), mid- (n = 8) and term pregnancies (n = 12).
Expression of the identified 16 mid-gestation specific loci was
further analyzed in REPROMETA placental samples representing
pregnancies with affected fetal growth (SGA, LGA) or maternal
complications (PE and GDM).
Quantitative gene expression was assessed by biplex qPCR of
target sequence and housekeeping gene HPRT1 (hypoxanthine
phosphoribosyltransferase 1) as a reference (assay ID: 4326321E,
Applied Biosystems, Foster City, CA, USA). All qPCR reactions
were performed in triplicate in 384 micro-well plates in ABI
7900HT Real-time PCR system (Applied Biosystems, Foster City,
CA, USA) using HOT FIREPolH Probe qPCR Mix (Solis
BioDyne, Tartu, Estonia) and commercially available premade
TaqMan Gene Expression Assays (Applied biosystems, Foster
City, CA, USA) for 24 tested and the one reference gene HPRT1
(Table S2). Negative controls contained either RNA that was not
reverse transcribed or lacked template inputs. RT-qPCR reactions
were initially denaturated at 95uC for 15 min, followed by 40
cycles of 15 s at 95uC and 1 min at 60uC. Relative quantification
was determined by using the standard curve method. In our
experiments, the reference gene HPRT1 was expressed at
approximately the same level as the selected genes of this study.
Statistical Analysis of RT-qPCR Data
Relative mRNA expression values were determined by
comparative CT method, that accounted for mean values of
normalized expression calculated by averaging three indepen-
dently measured normalized expression values of the triplicate
[21]. Q-Gene software was used for calculations and efficiency
corrections (BioTechniques, Carlsbad, CA, USA).
The statistical analyses were performed using statistical package
R version 2.9.0. First, ANOVA F-test was used to estimate the
linear function of gestational age from early to mid-gestation
samples (n = 31; gestational days 38 to 147). Second, significance of
RT-qPCR measurements among the placental samples represent-
ing first (n = 23), second (n = 8) and third trimester (n = 12)
pregnancies was assessed by Student t-test (no adjustment with
covariates). Genes with significant results in t-tests were further
studied in covariate analysis. Analysis of covariance (ANCOVA)
was applied to incorporate confounding effects between REPRO-
META control group of uncomplicated pregnancies and the four
study groups of pregnancy complications (SGA, LGA, PE, and
GDM). First, individual confounding effects were discovered
through statistical analysis of control and patient groups. Mann-
Whitney U-test was used to compare continuous phenotypic
covariates, and Fisher’s exact test was applied to compare
categorical covariates. Second, significant confounding effects
were studied with ANCOVA analysis independently for each
complication group, by comparing null and alternative models of
predicting gene expression values. The null model contained a
linear combination of all selected confounding covariates as
predictors, and the alternative model contained an additional
factor term reflecting the disease states of the samples (normal vs.
complicated). The difference in fits of null and alternative models
was quantified by the F-test, reflecting the importance of disease
states in association to gene expression and related confounding
variables. ANCOVA tests for all groups were adjusted by gestation
age, placenta weight, infant gender and type of delivery.
Differential expression testing in GDM group was additionally
adjusted by infant weight and maternal age, and in PE group with
infant weight. FDR correction for multiple testing was used
separately for each complication group to reduce the number of
false positive associations. Results with P-values P#0.05 were
considered significant.
Measurement of STC1 Protein Expression in Maternal
Plasma by ELISA and Statistical Analysis
Plasma samples collected on the day of delivery were analyzed
for STC1 protein levels in 83 REPROMETA study participants
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including the controls of uncomplicated pregnancies (n = 40) and
the four patient groups with fetal (SGA, n = 27; LGA, n = 16) or
maternal (PE, n = 16, GDM, n = 30) pregnancy complications
(Table 1). STC1 protein expression was measured using DuoSet
ELISA development kit (#DY2958, lot #1215530; R&D Systems
Europe, Ltd., Abingdon, UK) following manufacturer’s instruc-
tions. Experimental details are given in Text S2.
Statistical analysis of STC1 protein expression levels was carried
out similarly to RT-qPCR analysis described above, except that
different sets of covariates were used in ANCOVA analysis. Tests
for all complication groups were adjusted by the type of delivery
and maternal weight. In the SGA and LGA study groups, tests
addressing differential plasma levels of STC1 were additionally
adjusted by gestational age. In the GDM study group, tests were
corrected for the infant weight and maternal age, and in the PE
group for infant weight, gestational age and maternal height. FDR
multiple testing correction was used for all tests. Results with P-
values P#0.05 were considered significant.
Immunohistochemical Localization of LYPD6 and CCNG2
Proteins
Immunohistochemical (IHC) staining was performed using
6 mm placental paraffin sections sampled from five control, five
preeclamptic (PE) and five gestational diabetes mellitus (GDM)
pregnancies at term (Table S1). Placental tissue samples used for
IHC staining originated from the same tissue block as samples
collected for RNA extractions. Anti-human LYPD6 antibody
(1:30, LS-C102542, LifeSpan BioSciences, Seattle, USA) and
Dako REALTM EnVision Detection System kit (DakoCytomation,
Denmark) were used for LYPD6 IHC staining. Primary anti-
human CCNG2 (Santa Cruz Biotechnology, sc-7266, 1:100) and
secondary biotinylated polyclonal rabbit anti-goat antibodies
(DakoCytomation, Denmark, E 0466, 1:400) and LSAB2
System-HRP kit (DakoCytomation, Denmark) were used for
CCNG2 IHC staining. All IHC stainings were conducted
following manufacturer’s instructions; details are provided in
Text S3. Standard hematoxylin-eosin staining was used to
describe histological features characteristic to normal, PE and
GDM placentas at term. Imaging was performed with the
Olympus BX60 microscope using Olympus DP71 digital camera
and CellA imaging software (Olympus Optical). Microscope
magnifications 6100 and 6400 were used. All measurements
were acquired at the same light intensity and processed
consistently. The IHC staining pattern of LYPD6 and CCNG2
proteins in the placental sections neither from control, PE nor
GDM pregnancies depended on the mode of delivery.
Accession Numbers for Microarray Data
[GSE22490, GSE37901].
Results
Temporal Dynamics of Gene Expression in Placenta from
Early to Mid-pregnancy
Transcriptome profiling of ten placental tissue samples collected
at gestational ages from week 5 to 18 [gestational days: 38, 55,
2656, 81, 91, 120, 121, 126, 132] was conducted using GeneChip
(AffymetrixH; ,47,000 transcripts) expression arrays. Quantitative
microarray analysis of gene expression dynamics across the studied
gestation period identified 180 placental transcripts (representing
154 genes) with significant change in expression levels (ANOVA,
FDR corrected P,0.1, n = 10 samples), including 105 genes with
gradually increasing and 49 genes with decreasing transcript levels
(Figure 1, Table S2).
The most significant increase in expression was detected for the
FST (follistatin) gene (FDR P = 0.0068; fold change, fc = 7.16;
Figure 2A). Significant (FDR P,0.05) over 6-fold increase in
placental expression was also identified for NRCAM (neuronal cell
adhesion molecule; FDR P = 0.037; fc = 9.06), SLC16A10 (solute
carrier family 16 member 10; FDR P = 0.049; fc = 7.11), GPR183
(G protein-coupled receptor 183; FDR P = 0.049; fc = 6.96) and
ITGBL1 (integrin, beta-like 1; FDR P = 0.037; fc = 6.06). Among
the genes with borderline statistical evidence (FDR 0.05#P,0.1)
for increasing placental expression and with known effect on fetal
development, BMP5 (two Affymetrix probesets: fc = 58.89; 13.36),
GATM (fc = 9.32; 7.84), STC1 (fc = 6.92; 2.57) and MEG3 (three
probesets: fc = 10.63; 8.28; 3.14) stood out with considerable
change in transcript levels (Figure 2B; Table S2). The multiple
Affymetrix probe sets targeting BMP5 and MEG3 hybridize to
different splice variants of the gene (Figure S2). Alternative
MEG3-transcribed non-coding RNA-s have been implicated in
tissue-specific expression patterns [22]. The genes highlighted in
the GeneChip analysis are also similar according to the
hierarchical clustering of dynamic expression profiles across
gestational weeks 5 to 18 (Figure 1). Full names and descriptions
of all relevant genes are provided in Table 2 and Table S3.
Alternatively, microarray data were analyzed in two groups of
early (n = 6) and mid-gestation (n = 4) samples. As a result, 205
genes with significantly increased expression and 24 genes with
significantly decreased expression levels were detected (empirical
Bayes moderated t-test, FDR P,0.1; Figure S3, Table S4). The
group-based analysis recovered 63 (60%) significantly up-regulated
genes from the first ANOVA-based analysis of dynamic gene
expression, confirming the validity of both statistical approaches
and highlighting additional genes with alternative modes of
expression. Detailed results of the group-based analysis are
provided in Text S1, Figure S3, Table S4 and Table S5.
Genes for the further experimental confirmation and replication
by Taqman RT-qPCR were selected from top candidates of
gestation-age-dependent dynamic analysis (ANOVA). Out of 24
genes selected for RT-qPCR validation, 17 genes were also
significant in group-based analysis.
Gene Ontology and Pathway Analysis of Differentially
Expressed Genes
Functional enrichment analysis with g:Profiler software [17]
revealed more than 200 Gene Ontology (GO) categories and
pathways that are statistically over-represented in the list of genes
with dynamically increasing transcript levels. Many broad
biological processes (GO category type BP) are characteristic to
evolving placenta in pregnancy progression such as ‘cell commu-
nication’ (n = 42 genes, FDR P = 1.2661025, hypergeometric test)
and ‘multicellular organism development’ (n = 37 genes, FDR
P = 1.761025), ‘cellular response to stimulus’ (n = 43, FDR
P = 1.961025) and ‘cell surface receptor signaling’ (n = 26, FDR
P = 6.561025), ‘cell adhesion’ (n = 15, FDR P = 1.961024) and
‘migration’ (n = 11, FDR P = 0.011), ‘anatomical structure devel-
opment’ (n = 33, FDR P = 4.361024) and ‘growth’ (n = 12, FDR
P = 2.461023) (Table S6). The analysis also highlights several
specific processes related to pregnancy development and mainte-
nance, such as ‘blood vessel development’ (n = 9, FDR
P = 4.861023), ‘VEGF receptor signaling’ (n = 4, FDR
P = 7.761024), ‘gonadotropin secretion’ (n = 2, FDR P = 0.016)
and ‘superoxide metabolic processes’ (n = 3, FDR P = 0.014). In
contrast to high number of processes and pathways enriched
among the genes with dynamically increasing transcript levels
from early to mid-pregnancy, substantially fewer biological
processes represent the list of genes with decreasing expression.
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The most significant enrichment was detected for genes related to
‘transcription from RNA polymerase III promoter’ (FDR
P = 1.761024), although all four identified genes from this
pathway exhibit modest decrease in transcript levels (fc = 0.7–
0.75; Table S2).
Identification of Mid-pregnancy Specific Placental Genes
In total, 24 genes were selected for RT-qPCR analysis of
placental samples representing three gestational trimesters
(Figure 2; Table S3). The analysis included 14 genes with
highly significant gradual expressional change in placenta from
early to mid-pregnancy (ANOVA analysis of microarray data,
FDR P,0.05; Table S2). RT-qPCR experiments included
additional ten genes with mildly significant evidence of transcrip-
tional increase (ANOVA FDR 0.05#P,0.098) in pregnancy
progression towards second trimester (details in Materials and
Methods). To confirm the differential expression between the
first and the second trimester placentae of the selected genes based
Figure 1. Placental genes with considerable expressional change in progression from early to mid-pregnancy. Ten placental tissue
samples subjected to dynamic linear transcriptome expression profiling (Affymetrix HG-U133 plus 2.0 GeneChips) represented gestatational weeks of
5 (38 days), 8 (days 55, 56, 56), 11 (81 days), 13 (91 days), 17 (days 120, 121) and 18 (days 126, 132). The heatmap shows 154 genes (180 probe-sets)
with significant gradual increase (red) or decrease (blue) in placental transcription in first and second trimester placentas (ANOVA, FDR corrected
P,0.1). Color intensity reflects mean log2 fold change in gene expression with one first trimester sample (week 5; 38 gestational days) as reference.
For the placental samples collected at close gestational age, log2 fold change calculations represent the median values of 2–3 samples (55/56/56;
120/121; 126/132 gestational days). Hierarchical clustering with Euclidean distance, visualized by the dendrogram on the left, clearly separated genes
with increased and decreased expression. Colorstrip on the right of the heatmap highlights genes with strongest statistical significance of differential
expression. A subset 24 genes selected for further experiments are labeled on the vertical axis.
doi:10.1371/journal.pone.0049248.g001
Figure 2. Temporal quantitative gene expression changes in discovery samples over gestational weeks 5–18. Log2 fold changes
between Affymetrix GeneChip transcription values were calculated to estimate the direction of gene expression. Gene expression level at week 5
(gestational day 38) were used as a baseline. For the placental samples collected at close gestational age, fold change calculations represent the
median values of 2–3 samples (week 8: 55/56/56 gestational days; week: 17; 120/121 gestational days; week 18: 126/132 gestational days). (A) 14
genes with significant change in transcription (ANOVA, FDR corrected P,0.05, n = 10) and (B) additional 10 genes with known effect on pregnancy
that showed mildly significant differential expression (FDR corrected P,0.1) were selected for subsequent RT-qPCR analysis (Table S2). Genes are
ordered by decreasing P-value.
doi:10.1371/journal.pone.0049248.g002
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on microarray analysis, we used an expanded set of early (n = 23,
median gestational age 8 weeks, 6 days) and mid-pregnancy
samples (n = 8, median gestational age 18 weeks, 5 days;
Materials and Methods). Expressional change was tested
using both, dynamic (ANOVA) and group-based (Student t-test)
statistical approaches. In order to follow the expressional dynamics
of mid-gestation genes throughout the course of pregnancy, the
expression levels were determined additionally in term placentas
from uncomplicated pregnancies (Controls, n = 12; median gesta-
tional age 40 weeks, 1 day; Table 1A).
Among the 24 tested genes, 16 were confirmed with significant
differential expression between the first and the second trimester
placenta (ANOVA and t-test, FDR P,0.005; Figure 3; Figure 4;
Table S7). The most significant increase in gene expression in
mid-gestation compared to early pregnancy was detected for FST,
MEG3, PLAGL1, ITGBL1, BMP5 and STC1 known to contribute
to fetal development and growth, as well as for humoral immunity
related GPR183 and transcriptional regulator LYPD6 (ANOVA,
FDR P#761028; t-test, FDR P#8.761025; fc = 2.21–6.36;
Figure 3; Figure 4; Table 2; Table S7). Additionally, the
analysis revealed a significant activation of CDH11, SLC16A10,
NRCAM and GATM also regulating embryonic development and
growth, as well as ZFP36L1, CCNG2, NEDD9, NR3C1 (nuclear
receptor subfamily 3, group C, member 1) involved in cell cycle
regulation, proliferation and RNA metabolism, such as (ANOVA,
FDR P#0.0016; t-test, P,561023; fc = 1.41–2.99) (Figure 3;
Figure 4; Table 2; Table S7).
Ten genes (BMP5, CCNG2, CDH11, FST, GATM, GPR183,
ITGBL1, PLAGL1, SLC16A10, STC1) showed a clear peak of
placental gene expression at mid-gestation, followed by a 1.4 to
4.2-fold decrease in transcript levels at term (t-test, FDR P,0.05;
Figure 4A, Table S7). The most drastic drop in gene expression
Table 2. Molecular functions of identified mid-gestation marker genes in placenta and their involvement in clinical conditions.
Short name Full name Biological functiona Related disease or clinical conditiona
BMP5 Bone morphogenetic
protein 5
Bone, cartilage and limb development,
skeletal growth
Axial skeletal abnormalities, rheumatoid arthritis, osteoarthritis,
hypertensive nephrosclerosis; heterotopic ossification; pancreatic,
prostate and breast cancer
CCNG2 Cyclin-G2 Negative regulation of cell cycle, adipogenesis;
proliferation and differentiation of uterine
cells in implantation and decidualization
Thyroid carcinoma, gastric, oral, breast and ovarian cancer
CDH11 Cadherin-11 Cell adhesion, bone formation, growth,
main-
tenance and morphology, tumor suppressor
Osteoarthritis, osteosarcoma, glioblastoma, retinoblastoma, metastasis
of prostate and breast cancers, pulmonary fibrosis
FST Follistatin Inhibition of FSH release, folliculogenesis,
bone mineralization, muscle growth
Polycystic ovary syndrome, fertility, recurrent miscarriage, metastasis of
prostate cancer, osteoarthritis
GATM Glycine amidino-transferase Creatine biosynthesis, kidney function,
nervous system development
Heart failure, chronic kidney disease, mental retardation
GPR183 G-protein coupled
receptor 183
Humoral immunity Type 1 diabetes
ITGBL1 Integrin beta-like 1 Cell adhesion Growth hormone deficiency
LYPD6 LY6/PLAUR domain
containing 6
Transcriptional regulation; inhibition of tumor
promotion




Non-coding RNA, negative regulation of cell
proliferation, embryonic development, tumor
suppressor
Type 1 diabetes, pituitary tumor, meningioma, acute myeloid leukemia;
imprinting defects affect embryonic development
NEDD9 Neural precursor cell
expressed developmentally
down-regulated 9
Tyrosine-kinase-based signaling related to cell
adhesion, proliferation
Alzheimer’s and Parkinson’s disease; melanoma, head and neck
squamous cell carcinoma, glioblastoma, colon cancer
NR3C1 (GR) Nuclear receptor subfamily
3 group C member 1
(glucocorticoid receptor)
Transcriptional regulation, chromatin
remodeling, cellular proliferation and
differentiation, inflammatory response
Generalized glucocorticoid resistance; coronary heart disease; rheumatic
diseases; obesity; asthma, colorectal cancer, acute lymphoblastic
leukemia, adrenocortical carcinoma
NRCAM Neuronal cell adhesion
molecule





Transcription factor, apoptosis, embryonic
development and growth; cell cycle arrest,
cardiac morphogenesis, development of
pancreas
Imprinting defects affect embryonic development; overexpression in
fetal development leads to transient neonatal diabetes mellitus; ovarian,
breast and gastric cancer, melanoma, astrocytoma, pancreatic
adenocarcinoma, renal cell carcinomas, capillary hemangioblastoma,
pituitary adenoma, B-cell non-Hodgkin’s lymphomas
SLC16A10 Solute carrier family 16
member 10
Aromatic amino acids transport,
thyroid hormone transport
Intrauterine growth restriction
STC1 Stanniocalcin 1 Renal and intestinal Ca2+/P homeostasis, bone
and muscle development, kidney function,
gestational and nursing state regulator
Chronic kidney disease, heart failure; colorectal, ovarian, hepatocellular
and breast cancer, squamous cell carcinoma; reduced postnatal growth,
affected female reproductive potential; overexpression in mice leads to
dwarfism and increased metabolic rate
ZFP36L1 Zinc finger protein 36
C3H type-like 1 (butyrate
response factor-1)
regulation of translation; RNA metabolic
process; regulation of mRNA stability
and decay
Acute myelogenous leukemia, T-cell leukemia/lymphoma, breast
cancer; lack of expression in midgestation results in abnormal
placentation and fetal death
aReferences are listed in Table S9.
Mid-Gestation Placental Gene Expression
PLOS ONE | www.plosone.org 8 November 2012 | Volume 7 | Issue 11 | e49248
characterizes STC1 and CDH11 (FDR P,0.0003). The expression
of four genes (LYPD6, MEG3, NRCAM, ZFP36L1) was maintained
at the mid-gestation level until delivery (Figure 4B). Transcript
levels of NEDD9 and NR3C1 continued gradual increase until the
end of gestation (FDR corrected P,0.002; fold changes 1.4 and
1.68, respectively; Figure 4C).
Increased Placental Expression of Mid-gestation Genes in
Pregnancy Complications
We hypothesized that the normal course of late pregnancy may
be affected when the genes characteristic to mid-gestation
placental transcriptome remain highly expressed until term. The
hypothesis is based on the assumption that late pregnancy
complications may be accompanied by either of the two scenarios:
insufficient down-regulation of mid-gestation specific genes that
would normally undergo rapid inhibition at term, or continued
transcriptional up-regulation of genes that would normally reach
their expressional plateau already in mid-pregnancy. This
hypothesis was tested by comparing the gene expression of the
identified mid-term specific genes in term placentas of normal and
complicated pregnancies representing affected fetal growth (small-
and large-for-gestational-age newborns; SGA, LGA) or maternal
pregnancy disturbances (preeclampsia, PE; gestational diabetes
mellitus, GDM) (Table 1A, Table 2, Figure 3, Figure 4).
Among the tested genes, seven loci exhibited significantly higher
placental expression in pregnancy complications compared to the
control group (t-test; Table 3). Three genes (STC1, CCNG2,
Figure 3. Genes with significant dynamic increase in expression during early and mid-gestation as experimentally confirmed by RT-
qPCR. Relative mRNA expression levels in the extended sample set of first and second trimester placentas (n = 31; from gestational days 38 to 147)
were determined by TaqMan assays. P-values were calculated by ANOVA and subjected to multiple testing correction (FDR). Genes below the
significance threshold of P-value.0.02 are shown in Figure S4.
doi:10.1371/journal.pone.0049248.g003
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LYPD6) maintained significant differential expression in more than
one pregnancy complications also after FDR correction and
adjustment for multiple confounding factors (details of ANCOVA
analysis are provided in Materials and Methods). STC1 with
the sharp placental expression peak in mid-gestation (Figure 4A)
showed significantly higher expression in term placentae of all
studied pregnancy complications compared to normal gestation.
In the placentae of preeclamptic mothers (t-test, P = 2.661024;
fc = 1.51; Table 3) and in the SGA group (t-test P = 6.661024;
fc = 1.74) the transcript level of STC1 compared to control
placentae remained significantly increased after correction for
multiple testing (FDR P,0.05). Increased placental expression of
STC1 was also significantly associated with the SGA group when
all relevant confounding factors were considered (ANCOVA, FDR
P,0.05; Table 3). STC1 encodes a glycoprotein hormone
regulating renal and bone development and metabolism [23].
Higher expression of STC1 was also detected in the LGA
(P = 0.0082; fc = 1.41, t-test) and the maternal GDM groups
(P = 0.021; fc = 2.54), but these observations did not remain
significant after correction for multiple testing and confounding
effects (ANCOVA; Table 3). Cell cycle inhibitor CCNG2 showed
significantly increased expression in placentas obtained from
pregnancies complicated by maternal PE (t-test P = 4.361024;
FDR P,0.05; fc = 1.49) or GDM (P = 5.761024; FDR P,0.05;
Figure 4. Expressional dynamics of identified mid-pregnancy specific genes in placenta from early to term gestation. Relative mRNA
levels were determined by RT-qPCR TaqMan assays in placental tissues from early- (5–13 gestational weeks; n = 23), mid- (17–21 gestational weeks;
n = 8) and term-gestation (36–41 gestational weeks; n = 12) samples of uncomplicated pregnancy cases. Boxplots show mid-gestation marker genes
with (A) significantly increased mRNA expression compared to early- or late-gestation placental samples, (B) significantly increased expression levels
compared to early gestation placental samples, and (C) gradual increase in expression during pregnancy. P-values were calculated by Student t-test
and subjected to multiple testing correction (FDR) (Table S7).
doi:10.1371/journal.pone.0049248.g004
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fc = 1.46), and also from deliveries resulted in the birth of LGA
babies (P = 0.027, fc = 1.23). This observation was significant also
when confounding effects were considered (ANCOVA, FDR
P,0.05; Table 3). Significantly higher placental mRNA level of
the transcription regulator LYPD6 [24] was identified in all patient
groups: GDM (t-test: P = 1.361025; FDR P,0.05; fc = 1.79), PE
(P = 0.0024; FDR P,0.05; fc = 1.38), LGA (P = 0.0095; fc = 1.5)
and SGA (P = 0.014; fc = 1.57). In the SGA group, differential
placental expression of LYPD6 maintained statistical significance
after correcting for confounding effects (ANCOVA, FDR P,0.05;
Table 3).
Four further genes (GATM, GPR183, MEG3, CDH11) were
identified with a considerable trend for aberrantly increased
expression in placentas from complicated pregnancies, although
statistical tests for group comparisons did not remain significant
after correction for multiple testing (FDR P.0.05). Transcript
level of GATM was higher in all studied pregnancy complications
compared to normal term placentas (t-test; PE: P = 0.025,
fc = 1.41; GDM: P = 0.024, fc = 2.08; SGA: P = 0.022, fc = 1.49;
LGA: P = 0.019, fc = 1.44; Table 3). GATM encodes a mitochon-
drial enzyme involved in creatine biosynthesis (Table 2). GPR183
contributing to humoral immunity showed an increased placental
Table 3. Mid-gestation marker genes with increased mRNA expression levels in term placenta of pregnancy complications
compared to placentas of uncomplicated gestationsa.









STC1 PE 0.00026 0.014 0.47 0.89 1.51
GDM 0.021 0.12 0.022 0.06 2.54
SGA 0.00066 0.014 0.00077 0.0054 1.74
LGA 0.0082 0.087 0.053 0.34 1.41
CCNG2 PE 0.00043 0.014 0.0019 0.013 1.46
GDM 0.00057 0.014 0.00019 0.0013 1.49
SGA 0.1 0.28 0.081 0.12 1.21
LGA 0.027 0.12 0.14 0.34 1.23
LYPD6 PE 0.0024 0.035 0.15 0.52 1.38
GDM 0.000013 0.0017 0.026 0.06 1.79
SGA 0.014 0.1 0.0075 0.026 1.57
LGA 0.0095 0.087 0.41 0.48 1.5
GATM PE 0.025 0.12 0.87 0.97 1.41
GDM 0.024 0.12 0.041 0.072 2.08
SGA 0.022 0.12 0.043 0.08 1.49
LGA 0.019 0.11 0.14 0.34 1.44
GPR183 PE 0.15 0.36 0.77 0.97 1.29
GDM 0.1 0.28 0.088 0.1 1.41
SGA 0.025 0.12 0.057 0.08 1.52
LGA 0.029 0.12 0.21 0.34 1.41
MEG3 PE 0.13 0.33 0.97 0.97 1.42
GDM 0.012 0.1 0.26 0.26 2.13
SGA 0.067 0.22 0.054 0.08 3.13
LGA 0.096 0.28 0.24 0.34 1.54
CDH11 PE 0.14 0.34 0.51 0.89 1.23
GDM 0.026 0.12 0.069 0.096 1.55
SGA 0.26 0.51 0.18 0.18 1.18
LGA 0.68 0.83 0.99 0.99 1.07
aMid-gestation marker genes with statistically non-significant results are given in Table S8.
bCases included maternal pregnancy complications (preeclampsia, PE, n = 12; gestational diabetes mellitus, GDM, n = 12), fetal pregnancy complications (small-for-
gestational-age, SGA, n = 12; large-for-gestational-age, LGA, n = 12), as well as control samples comprised of uncomplicated pregnancies resulting in the birth of an
appropriate-for-gestational-age newborn (AGA, n = 12).
cP-values from RT-qPCR data were estimated with Student t-test (no adjustment). For seven genes with significant t-test P-values, analysis of covariance (ANCOVA)
adjusted by estimated confounder effects was used. All tests were adjusted by gestation age, placenta weight, infant gender and type of delivery. In case of GDM, tests
were additionally adjusted by infant weight and maternal age, and with infant weight in case of PE. Bold letters highlight the genes with statistically significant values
throughout analyses. T-test FDR correction considered 16 genes. ANCOVA FDR considered 7 genes.
dFold change was calculated as the difference of mean relative expression values of each pregnancy complication vs control group of uncomplicated pregnancies.
doi:10.1371/journal.pone.0049248.t003
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expression in affected fetal growth (SGA, P = 0.025, fc = 1.52;
LGA, P = 0.029, fc = 1.41). The expression of the imprinted non-
coding RNA encoding MEG3 and cell-cell adhesion mediating
CDH11 were increased in GDM cases (P = 0.012, fc = 2.13 and
P = 0.026, fc = 1.55, respectively).
Other tested mid-gestation genes (BMP5, FST, ITGBL1,
NEDD9, NR3C1, NRCAM, PLAGL1, SLC16A10, ZFP36L1) showed
no clear trend for the difference in expression levels between
complicated pregnancies and the control group (Table S8).
The three genes (STC1, CCNG2, LYPD6) with the strongest
association to increased transcription in term placentae of
complicated pregnancies were selected for validation of protein
expression, either in maternal plasma by ELISA (STC1) or in
placenta tissue samples by immunohistochemistry (IHC) (CCNG2,
LYPD6).
Significantly Elevated Maternal Plasma STC1 Level in
Pregnancy Complications
Circulating STC1 is induced during gestation and lactation in
mice, indicating its potential role as a regulator of metabolism in
pregnancy [25]. In Human Protein Atlas (http://www.
proteinatlas.org/), the placental expression of human STC1 is
shown in cytoplasm and membranes of trophoblasts as well as in
decidual cells [26]. Here we asked whether the increase in
placental STC1 mRNA in pregnancy complications correlates with
the higher maternal circulating STC1 levels. The concentration of
soluble secreted glycoprotein hormone STC1 [27] was measured
by ELISA in post-partum maternal plasma samples of PE and
GDM patients or mothers of newborns with affected intrauterine
growth (SGA, LGA) (Table 1B). Median concentration of STC1
protein in plasma in the GDM (median 690 pg/ml, range 263–
1183; ANCOVA, P = 0.026) and the PE group (median 773 pg/
ml, range 332–1715; ANCOVA, P = 0.035) was significantly
elevated compared to control samples (median 418 pg/ml, range
124–1125) (Figure 5A). Significantly increased level of plasma
STC1 was also detected in uncomplicated pregnancies resulting in
the birth of a SGA, in comparison to controls (median 650 pg/ml,
range 373–1355; ANCOVA, P = 0.0082). Mothers in the LGA
group showed a nearly significant trend for the increased STC1
levels (median 532 pg/ml, range 305–1029; P = 0.065)
(Figure 5A).
Preeclampsia and gestational diabetes mellitus may occur solely
as a maternal disease or in combination with affected fetal growth
(PE-SGA, GDM-LGA) [28,29]. When PE cases were grouped
based on the birth-weight of newborns, increase in maternal
plasma concentrations of STC1 was strongly more pronounced in
the PE-SGA group (median 731 pg/ml, range 1108–1715;
ANCOVA, P = 0.00048) (Figure 5B). In contrast, when GDM
patients were further classified based on the delivery of large
(GDM-LGA) or normal-weight baby, the statistical significance of
the higher maternal STC1 was enhanced in neither of the
subgroups compared to the full GDM group analysis. (Figure 5C).
Expression and Localization of LYPD6 and CCNG2
Proteins in Term Placental Tissue from Normal and
Complicated Pregnancies
To determine protein expression levels of cytoplasmic molecules
of LYPD6 [24] and CCNG2 [30], immunohistochemical (IHC)
staining was performed in placental sections from control (n = 5),
GDM (n = 5) and PE (n = 5) pregnancies. Characteristics of the
IHC study groups are provided in Table S1.
LYPD6 antibody showed a strong cytoplasmic and nuclear
staining of placental villous Hoffbauer cells, fibroblasts and
endothelial cells of villous vessels. Most importantly, all types of
chorionic villi exhibited a diffuse cytoplasmic LYPD6 staining of
syncytiotrophoblasts. Although the placental cellular localization
of LYPD6 did not differ among the study groups, the staining
intensity of the LYPD6 antibody was notably stronger in placental
sections from all studied five PE and five GDM cases (Figure 6B;
Figure S5). This observation is consistent with RT-qPCR results
showing significant increase in LYPD6 transcript levels in GDM
and PE (Table 3).
The CCNG2 antibody staining revealed a fine granular
cytoplasmic expression of CCNG2 in villous stromal Hoffbauer
cells and fibroblast cells. Intermediate villi enriched in stromal cells
exhibited stronger staining compared to small terminal villi. In
addition, weak cytoplasmic staining of syncytiotrophoblast and
endothelial cells of blood vessel walls was detected. The cellular
localization of CCNG2 in placenta was similar in all study groups.
The staining intensity, however, was stronger in all PE and GDM
placental sections compared to control samples, consistent with the
differential expression at the mRNA level (Figure 6C, Table 3,
Figure S6).
Discussion
Placenta is a temporary organ with rapid changes in structure
and function across relatively short lifespan to support the
establishment and the normal progression of pregnancy until
delivery. However, information on the temporal dynamics of
placental gene expression is scarce. Only three published studies
have focused on differential expression at term compared to the
first or the second trimester placenta [10–12], and there is only
one published report addressing differential expression between
the first and second trimester placentas with no attempt to provide
experimental validation of microarray experiments [12].
This is the first study that reports quantitative profiling of
placental transcriptome dynamics across three months from early
to mid-pregnancy (10 samples; gestational weeks 5 to 18). The
main strengths of the present analysis compared to the previous
report [12] involve the experimental validation of selected top
genes from microarray analysis, and further replication of mid-
gestation expression in an extended sample-set representing first,
second and term placentae (n = 43; gestational weeks 5 to 41).
However, a number of limitations restrict the interpretation of our
results. The current study covers only a relatively small number of
mid-gestation placental samples (n = 8) as the acquisition of such
rare human samples involves major clinical and ethical restric-
tions. In addition, trophoblast samples collected after early
termination of pregnancy may include contamination of maternal
cells. Unfortunately no generally agreed placental reference genes
are currently available with known stable expression profile over
all three trimesters of pregnancy. In Taqman RT-qPCR
conformation experiments, we used HPRT1 as a reference gene,
assuming its constant expression in pregnancy. In fact, HPRT1 has
been shown to maintain a stable expression level during early
pregnancy [31] and in term placenta when normal, PE and GDM
samples were compared [32]. We have successfully applied
HPRT1 as a reference gene to study of the expression of selected
placental genes in the first, second and third trimester [33].
Two alternative statistical approaches for gene expression
microchip analyses detected in total 154 genes (ANOVA, FDR
P,0.1; Figure 1, Table S2) and 229 genes (empirical Bayes
moderated t-test, FDR-corrected P,0.1; Figure S3; Table S4)
with significant change in gene expression from gestational week 5
to 18. The two analyses consistently demonstrated that the
majority of genes showed increasing transcript levels. Ten of the
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24 loci (Figure 2, Table S3) selected for confirmation
experiments in an extended sample set showed highly significant
expressional peak in mid-gestation placenta with a drop in
transcript levels at term (Figure 3; Figure 4). Among these,
CDH11 and STC1 [11,12], CCNG2 [11], SLC16A10 and FST [12]
have been reported previously to show significant reduction in
placental expression at term compared to mid-pregnancy.
Notably, several of the identified genes with specific expression
in mid-gestation placenta have been reported to be involved in
regulation of mammalian placental function and/or embryonic
development (Table 2, extended references in Table S9). STC1/
Stc1 encoding stanniocalcin 1 contributes to implantation process
in human [34], pigs [35] and sheep [36], and cyclin-G2 (gene
Ccng2) in mice [37]. Cadherin 11 coded by CDH11 functions in
trophoblast cell differentiation [38] and a lack of Zfp36L1
expression in murine midgestation results in abnormal placenta-
tion and fetal death [39]. Bone morphogenetic protein 5 (gene:
BMP5) [40], cadherin 11 (CDH11) [41], follistatin (FST) [42,43]
Figure 5. Glycoprotein hormone STC1 protein levels in maternal blood plasma. STC1 protein levels in maternal plasma from
uncomplicated pregnancies (defined as controls) compared to (A) pregnancies resulting in the birth of small-for-gestational-age (SGA) and large-for-
gestational-age (LGA) newborns, as well as pregnancies complicated with preeclampsa (PE) or gestational diabetes mellitus (GDM); (B) cases with PE
and (C) GDM grouped by newborn birth weight. Median values are indicated by horizontal bars. Plotted values are represented with no adjustment
for confounding effects. Statistical differences between controls and each of the patient groups were assessed by accounting for confounding factors
with ANCOVA. Statistical tests were adjusted for newborn birth-weight (initial analyses of PE and GDM cases), gestational age (SGA, LGA, PE), mode of
delivery and mother’s weight (all groups), height (PE, except when grouped by newborns birth weight) and age (GDM). The adjusted P-values are
given above the data point of the respective study group.
doi:10.1371/journal.pone.0049248.g005
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and stanniocalcin 1 (STC1) [23] contribute to bone formation,
mineralization and skeletal growth, as well as muscle development
and growth. STC1 and GATM (encoding glycine amidino
transferase) are involved in kidney and nervous system develop-
ment [23,44], and paternally expressed PLAGL1/Zac1 in cardiac
morphogenesis and the development of pancreas [20,45–47]. The
correct imprinting of maternally expressed imprinted MEG3 plays
a general crucial role in normal embryonic development and
growth [48,49].
An additional innovation of our study is the testing of a novel
hypothesis that late pregnancy complications may be accompanied
by abnormal placental expression of mid-gestation genes in late
pregnancy, such as insufficient down-regulation of genes that are
normally inhibited at term, or further up-regulation of genes that
normally reach a plateau of constant expression already in mid-
pregnancy. Our study strongly supports the idea that profound
changes are required in gene expression profile in normal term
compared to early- and mid-pregnancy placenta. The present
study investigated our postulated hypothesis in the context of
maternal pregnancy complications of preeclampsia (PE) and
gestational diabetes mellitus (GDM), as well as affected fetal
growth (LGA, SGA). The gene STC1 coding for stanniocalcin 1
(STC1) was identified with a sharp placental expressional peak in
mid-gestation (Figure 3; Figure 4) and increased mRNA levels
at term in all pregnancy complications compared to controls, with
the most significant effect in PE and SGA groups (Table 3).
Increased levels of placental STC1 in affected fetal growth detected
in the current study are consistent with the reduced fetal growth of
transgenic mice over-expressing human STC1 [50]. In agreement
with placental mRNA data, STC1 protein levels were elevated in
post-partum maternal plasma in PE, SGA and GDM pregnancy
complications (Figure 5). The glycoprotein hormone STC1
functions mainly in an autocrine/paracrine manner in many
organs and is implicated in regulation of calcium and phosphate
homeostasis [23]. Induction of circulating STC1 in murine
pregnancy has indicated its role in gestational metabolism [25].
Further underlining its importance in renal homeostasis [51,52],
we report significant increase in placental STC1 expression and in
maternal post-partum plasma STC1 in preeclampsia, known to be
accompanied by impaired renal function. It remains to be studied
whether elevated circulating STC1 in maternal plasma partially
originates from placenta or reflects maternal internal response to
PE pathophysiology. Although we conducted a small-scale study
based on biological material collected post-partum, the observed
significantly elevated maternal plasma levels of STC1 in pregnan-
cy complications warrant further investigations of its potential as a
prognostic biomarker of the pregnancy course. The only published
study on human circulating STC1 level has reported significantly
increased serum STC1 in ovarian cancer patients [53].
It is noteworthy that the highest plasma levels of STC1 were
measured for the cases, who had developed simultaneously
maternal PE and given birth to an SGA baby (median 731 pg/
ml vs 418 pg/ml in controls; ANCOVA, P = 0.00048). This data
refers to partially common pathologic origin for those conditions
[6,28]. A possible link to the up-regulation of STC1 in both
disturbed maternal and fetal metabolism may be stress conditions,
such as low oxygen concentrations. STC1 promoter harbors a
binding site for HIF-1 transcription factor regulating the genes
involved in cellular responses to hypoxia [54]. An earlier study
demonstrated the HIF-1 protein mediated activation of STC1
expression in hypoxic human cancer cells [55].
In addition to STC1, PE as well as GDM placentae were
characterized by significantly higher gene expression of LYPD6
(encoding LY6/PLAUR domain containing 6) and CCNG2
(Cyclin-G2) (Table 3), confirmed by the stronger staining
intensity of LYPD6 and CCNG2 antibodies on PE and GDM
placental sections in performed IHC experiments (Figure 6,
Figure S5, Figure S6). LYPD6 was identified as a novel protein
expressed in syncytiotrophoblast. The only published report on
LYPD6 showed that its over-expression suppresses activator
protein 1 (AP-1) -mediated transcriptional activity [24]. In normal
human placenta, AP-1 transcription factors are specifically
expressed in intermediate extravillous trophoblasts to regulate
their invasiveness [56], as well as proliferation and differentiation
of cytotrophoblasts [57]. Cyclin G2 inhibits cell cycle in response
to diverse growth inhibitory signals, such as heat shock, oxidative
stress, hypoxia, DNA damage and differentiation [30,58].
Increased expression of CCNG2 in placentas of pregnancy
complications may reflect local cellular stress conditions.
A recent study on mice revealed a new, direct role of placental
metabolic pathways in regulating fetal brain development by
placenta-derived serotonin and provided experimental evidence
for the role of maternal-placental-fetal interactions in develop-
mental programming of mental health [59]. Interestingly, the
majority of highly expressed genes in mid-gestation placenta
identified in the current study have been also linked to human
complex disease (Table 2; references in Table S9). These
observations promote speculations on a possible wider effect of
placental gene expression on the biological bases of developmental
origins of human disease [60]. Among the genes with the peak
expression in the mid-pregnancy followed by a drop at term,
BMP5 [61], CDH11 [62] and FST [63] are implicated in bone and
cartilage related disorders such as rheumatoid arthritis and
osteoarthritis. GATM and STC1 have been among the top loci in
genome-wide association studies of chronic kidney disease [51,52],
and have also been implicated in heart failure [64,65]. MEG3 [66]
and GPR183 [67] were shown to be involved in the development
of type 1 diabetes. Among the few genes which continued steady
rise in placental expression until term, NR3C1 coding for
Figure 6. The immunostaining of CCNG2 and LYPD6 proteins was assessed in placental sections from term pregnancies with no
complications (controls), with preeclampsia (PE) or with gestational diabetes mellitus (GDM). (A) Hematoxylin-eosin staining was used to
describe histopathological findings in analyzed placental samples (100-fold microscope magnification). In term placentae the mature intermediate
(IMV) and small terminal villi (STV) were seen. Characteristic to PE, villous agglutination and infarction (IN; intense eosinophilic staining) and increased
number of syncytial knots (SK) were detected. GDM presented with degenerative placental lesions such as focal villous fibrinoid necrosis (FN). (B)
Diffuse cytoplasmic staining of LYPD6 antibody was detected in syncytiotrophoblast (ST) cells in all villous types (IMV, STV). Additionally LYPD6
antibody strongly stained the cytoplasm and the nucleus of villous stroma Hoffbauer cells (H), fibroblasts (F) and endothelial cells (E) of villous vessels.
No localization differences in LYPD6 antibody stain between the groups were found; however strong tendency to higher staining intensity was
observed in PE and GDM placentas compared to normal term placenta. (C) CCNG2 antibody showed fine granular cytoplasmic staining of villous
stromal Hoffbauer (H) and fibroblast (F) cells. In addition, weak cytoplasmic staining of syncytiotrophoblast (ST) and endothelial cells (E) of vessel wall
was found. No localization differences in CCNG2 staining between the normal, PE and GDM groups were detected. Higher tendency to positivity was
seen in PE placental sections. (D) Negative control (NC) staining was performed without primary antibody. Scale bar, 100 mm. Microscope
magnifications6100 and6400 were used. Brown color indicates chromogen-labeled antibody and blue color indicates hematoxylin nuclear staining.
doi:10.1371/journal.pone.0049248.g006
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glucocorticoid receptor has been implicated in rheumatism [68]
and the malfunction of NRCAM and NEDD9 is related to brain
disorders such as autism [69], Alzheimer’s and Parkinson’s disease
[70,71]. Interestingly, LYPD6 is also located within a micro-
duplication region linked to developmental delay [72]. In addition,
the majority of midgestation-related genes are involved in various
types of cancer (Table 2, references in Table S9).
Conclusions
The study identified a pool of transcripts with a sharp
expressional peak in mid-gestation pregnancy and demonstrated
the importance of fine-scale tuning of the temporal dynamics of
placental transcriptional regulation relevant to each gestational
period. Interestingly, the majority of genes with high expression in
mid-gestation placenta have also been implicated in adult complex
disease, promoting the discussion on the role of placenta in
developmental programming [73]. The discovery of elevated
maternal plasma STC1 in pregnancy complications warrants
further investigations of its potential as a biomarker.
Supporting Information
Text S1 Group-based microarray analysis comparing
gene expression differences between early and mid-
gestation discovery samples.
(DOCX)
Text S2 Experimental details of ELISA measurements
of STC1 in maternal blood plasma.
(DOCX)
Text S3 Immunohistochemical characterisation of
LYPD6 and CCNG2 expression in human placenta.
(DOCX)
Figure S1 QC analysis of GeneChip gene expression
microarray data by exploring hybridization signal
distribution. Signal (log) intensities in arrays representing the
analyzed placental samples from mid-pregnancy (n = 4) are
illustrated by (A) boxplots of PM (perfect mismatch) intensities
(median value was 7), and (B) plots of kernel density estimates of
these intensities. QC included comparison of average intensity,
correlation with median intensity of other GeneChips, GAPDH 39–
.59 and b-actin 39–.59, scaling factor, percentage of presence
calls, average background and intensities of positive and negative
border elements.
(TIF)
Figure S2 Alternative splice forms of top genes with
significant expressional change from early to mid-
gestation placenta as identified by Affymetrix HU133
Plus 2 microarray probesets. Isoforms of 24 genes selected
for Taqman RT-qPCR experiments were matched to alternatively
spliced transcripts according to the Ensemble database version 68.
Orange indicates transcripts matched by a given probeset; asterisk
indicates probesets with a significant (FDR P,0.1 of ANOVA)
change in expression from gestational week 5 to 18 (gestational
days 38 to 132).
(TIF)
Figure S3 Volcano plot for the ,47,000 transcripts from
the group-based comparison of early (n = 6) and mid-
gestation (n = 4) samples. The X-axis shows the log2 fold
change (FC), while Y-axis represents FDR corrected P-value in –
log10 scale, computed using empirical Bayes moderated t-test. Out
of 24 genes selected for RT-qPCR validation based on the
ANOVA analysis of microarray data, 18 genes (showed in volcano
plot) were also significant in group-based analysis (FDR P,0.1).
(TIF)
Figure S4 Genes with insignificant expressional change
during early and mid-gestation as quantified by RT-
qPCR. Relative mRNA expression levels in extended sample set
of first and second trimester placentas (n = 31; from gestational
days 38 to 147) were determined by TaqMan assays. P-values were
calculated by ANOVA and subjected to FDR correction.
(TIF)
Figure S5 Immunostaining of LYPD6 protein was
assessed in term placental sections from uncomplicated
control, preeclampsia (PE) and gestational diabetes
mellitus (GDM) pregnancies. Diffuse cytoplasmic stain of
LYPD6 antibody was detected in syncytiotrophoblast (ST) cells in
intermediate (IMV) and small terminal (STV) villi. Additionally
LYPD6 antibody strongly stains cytoplasma and nucleus of villous
stroma Hoffbauer cells (H), fibroblasts (F) and endothelial cells (E)
of villous vessels. Brown staining indicates to chromogen-labeled
antibody and blue for hematoxylin nuclear stain. No difference in
the localization of LYPD6 antibody stain between the groups was
identified, but strong tendency to higher staining intensity in PE
and GDM placentas compared to normal term placenta was
observed. Scale bar, 50 mm. Microscope magnifications X100 and
X400 were used. IN, infarction lesion; SK, syncytial knot.
(TIF)
Figure S6 The immunostaining of CCNG2 protein was
assessed in term placental sections from uncomplicated
control, preeclampsia (PE) and gestational diabetes
mellitus (GDM) pregnancies. CCNG2 antibody has fine
granular cytoplasmic staining of villous stromal Hoffbauer (H) and
fibroblast (F) cells. Weak staining was detected in cytoplasm of
syncytiotrophoblast (ST) and endothelial cells (E) of vessel wall in
intermediate (IMV) and small terminal (STV) villi. No difference
in the localization of CCNG2 antibody stain between the groups
was identified, but strong tendency to higher staining intensity in
PE and GDM placentas compared to normal term placenta was
observed. Scale bar, 50 mm. Microscope magnifications X100 and
X400 were used. IN, infarction lesion; FN, fibrinoid necrosis.
(TIF)
Table S1 Maternal and offspring characteristics of
REPROMETA samples used in the study for immuno-
histochemistry experiments.
(DOCX)
Table S2 Differentially expressed placental genes on
AffymetrixH GeneChip. 154 genes (180 probe sets) detected on
AffymetrixH GeneChip exhibiting significant (ANOVA, FDR-
corrected P-value,0.05) or suggestive (P-value,0.1) increased or
decreased placental expression in the progress of pregnancy from
5th to 18th of gestational week. Fold change in gene expression
level as estimated between weeks 5 and 18 of gestational age. For
the genes selected for further experiments TaqMan probe sets used
in RT-qPCR experiments are provided.
(DOCX)
Table S3 Biological processes obtained from Gene
Ontology Annotation Database (www.ebi.ac.uk/GOA/) for
genes exhibiting significantly increased or decreased
placental expression in the progress of pregnancy from
5th to 18th of gestational week (ANOVA, FDR P,0.1) and
selected for RT-qPCR confirmation.
(DOCX)
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Table S4 Differentially expressed placental genes on
AffymetrixH GeneChip detected by group-based micro-
chip analysis comparing the first (n = 6; gestational days
38, 55, 2656, 81, 91) and the second (n = 4; gestational
days 120, 121, 126, 132) trimester discovery samples.
(DOCX)
Table S5 Functional enrichment analysis of up-regulat-
ed and down-regulated placental genes identified using
group-based analysis (empirical Bayes moderated t-
test) comparing early and mid-gestation discovery
samples. Gene Ontology terms and pathways with statistically
significant over-representation (FDR p,0.05, hypergrometric test)
were retrieved from g:Profiler, separately for genes with induced
and inhibited expression patterns. BP, biological process; CC,
cellular component; MF, molecular function; ke, KEGG pathway;
re, Reactome pathway.
(XLS)
Table S6 Functional enrichment analysis of up-regulat-
ed and down-regulated placental genes identified using
dynamic gestation-age dependent statistical analysis
(ANOVA). Gene Ontology terms and pathways with statistically
significant over-representation (FDR p,0.05, hypergrometric test)
were retrieved from g:Profiler, separately for genes with induced
and inhibited expression patterns. BP, biological process; CC,
cellular component; MF, molecular function; ke, KEGG pathway;
re, Reactome pathway.
(XLS)
Table S7 TaqMan RTqPCR analysis of genes selected
from placenta transcriptome micorarray anaysis.
(DOCX)
Table S8 The identified mid-gestation marker genes
showing no statistically significant difference in gene
expression between the term placental samples from
normal pregnancies and the pregnancy complications in
the REPROMETA sample collection.
(DOCX)
Table S9 Involvement of 16 detected mid-gestation
marker genes in adult complex traits and diseases.
(DOCX)
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